Skip to main content
AAN.com

Abstract

The DATATOP database, which includes clinical information on 800 patients with early untreated Parkinson's disease (PD), is well suited to explore clinical heterogeneity in PD. Patients with early-onset PD (≤40 years, N = 33) reached the same level of disability as the late-onset PD (≥70 years, N = 85) group at a significantly slower rate (2.9 vs. 1.7 years). Early-onset PD patients functioned cognitively better than late-onset PD patients. Bradykinesia, and postural instability and gait difficulty (PIGD), were more common at onset in patients with a rapid rate of disease progression (“malignant PD”; duration of symptoms <1 year and Hoehnflahr stage of 2.5, N = 11) as compared with those with a relatively slow rate of progression (“benign PD”; duration of symptoms >4 years, N = 65). Comparisons of tremor-dominant PD (mean tremor score/ mean PIGD score ≤1.5, N = 441) with the PIGD-dominant type (mean tremor score/mean PIGD score ≥1.0, N = 233) provided support for the existence of clinical subtypes. The PIGD group reported significantly greater subjective intellectual, motor, and occupational impairment than the tremor group. Stage II patients had higher depression scores than stage I patients. Among the patients participating in the DATATOP, older age at onset with bradykinesia, or with the PIGD form of PD, is associated with more functional disability than when the symptoms are dominated by tremor or begin at a younger age.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 40Number 10October 1990
Pages: 1529
PubMed: 2215943

Publication History

Published online: October 1, 1990
Published in print: October 1990

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

J. Jankovic, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
M. McDermott, PhD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
J. Carter, RN
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
S. Gauthier, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
C. Goetz, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
L. Golbe, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
S. Huber, PhD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
W. Koller, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
C. Olanow, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
I. Shoulson, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
M. Stern, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
C. Tanner, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
W. Weiner, MD
From the Department of Neurology, Baylor College of Medicine, Houston, TX.
Parkinson Study Group
From the Department of Neurology, Baylor College of Medicine, Houston, TX.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Caffeine and its potential use in Parkinson's disease, Tea in Health and Disease Prevention, (591-597), (2025).https://doi.org/10.1016/B978-0-443-14158-4.00027-0
    Crossref
  2. Association Analysis of Essential Tremor-Associated Genetic Variants in Sporadic Late-Onset Parkinson’s Disease, Tremor and Other Hyperkinetic Movements, 14, 1, (2024).https://doi.org/10.5334/tohm.885
    Crossref
  3. Serum Apo Lipoprotein E, Apo Lipoprotein E Gene Polymorphisms, and Parkinson’s Disease, Neurology India, 72, 2, (319-325), (2024).https://doi.org/10.4103/ni.ni_940_21
    Crossref
  4. Association Between Baseline Gait Parameters and Future Fall Risk in Patients With De Novo Parkinson’s Disease: Forward Versus Backward Gait, Journal of Clinical Neurology, 20, 2, (201), (2024).https://doi.org/10.3988/jcn.2022.0299
    Crossref
  5. Effect of Lee Silverman Voice Treatment® BIG on the major motor symptoms in patients with moderate Parkinson’s disease: an observational study, Journal of Gerontology and Geriatrics, 72, 2, (76-82), (2024).https://doi.org/10.36150/2499-6564-N711
    Crossref
  6. Neurocognitive Impairment and Social Cognition in Parkinson’s Disease Patients, Neurology International, 16, 2, (432-449), (2024).https://doi.org/10.3390/neurolint16020032
    Crossref
  7. Exploring the Spectrum of Visual Illusions and Other Minor Hallucinations in Patients with Parkinson’s Disease in Lithuania, Medicina, 60, 4, (606), (2024).https://doi.org/10.3390/medicina60040606
    Crossref
  8. The Effects of Multidisciplinary Intensive Rehabilitation on Cognitive and Executive Functions in Parkinson’s Disease: A Clinical Database Analysis, Journal of Clinical Medicine, 13, 13, (3884), (2024).https://doi.org/10.3390/jcm13133884
    Crossref
  9. Beta-gamma phase-amplitude coupling of scalp electroencephalography during walking preparation in Parkinson’s disease differs depending on the freezing of gait, Frontiers in Human Neuroscience, 18, (2024).https://doi.org/10.3389/fnhum.2024.1495272
    Crossref
  10. Simple biomarkers to distinguish Parkinson’s disease from its mimics in clinical practice: a comprehensive review and future directions, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1460576
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share